Tumor infiltrating lymphocytes (TILs) are associated with benefit to trastuzumab and chemotherapy in early-stage HER2+ breast cancer (BC) patients. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab (LT) treatment is unclear.
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy / De Angelis, C., Nagi, C., Hoyt, C.C., Liu, L., Roman, K., Wang, C., Zheng, Y.i., Veeraraghavan, J., Sethunath, V., Nuciforo, P., Wang, T., Tsimelzon, A., Mao, S., Hilsenbeck, S.G., Trivedi, M.V., Cataldo, M.L., Pavlick, A., Wolff, A.C., Weigelt, B., Reis-Filho, J.S., et al.. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 26:3(2020), pp. 738-745. [10.1158/1078-0432.CCR-19-1402]
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy
De Angelis, CarminePrimo
;Cataldo, Maria Letizia;
2020
Abstract
Tumor infiltrating lymphocytes (TILs) are associated with benefit to trastuzumab and chemotherapy in early-stage HER2+ breast cancer (BC) patients. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab (LT) treatment is unclear.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
